Requirement for expert histopathological assessment of ovarian cancer and borderline tumors.
AuthorsSengupta, P S
Shanks, Jonathan H
Buckley, C H
Ryder, W David J
Slade, Richard J
Kitchener, Henry C
Jayson, Gordon C
AffiliationDepartment of Medical Oncology, Christie Hospital National Health Trust, Withington, Manchester, UK.
MetadataShow full item record
AbstractThe distinction between borderline ovarian tumours (BOT) and ovarian carcinoma is made by histopathological assessment. Of 64 patients managed according to institutional BOT protocols, 27 (42%) had been referred with a diagnosis of ovarian carcinoma that was subsequently changed to BOT following histopathological review. The 70% 6-year event-free survival of the patients with a revised diagnosis was not significantly different from those who were referred with a diagnosis of BOT. This change in diagnosis is important as it avoids the need for chemotherapy for most patients and results in patients receiving appropriate information concerning prognosis. Interestingly, 24 patients (38.1%) reported a family history of epithelial cancer, a finding that has not been reported previously. Campaign
CitationRequirement for expert histopathological assessment of ovarian cancer and borderline tumors. 2000, 82 (4):760-2 Br. J. Cancer
JournalBritish Journal of Cancer
- Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
- Authors: Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S, EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm.
- Issue date: 2003 Jan 15
- [Clinical and pathological features of borderline ovarian tumors].
- Authors: Li Y, Cui H, Shen DH, Zhao Y, Wei LH, Qian HN
- Issue date: 2003 Feb
- The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
- Authors: Silva EG, Gershenson DM, Malpica A, Deavers M
- Issue date: 2006 Nov
- Recurrence and prognostic factors in borderline ovarian tumors.
- Authors: Ayhan A, Guvendag Guven ES, Guven S, Kucukali T
- Issue date: 2005 Sep
- Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
- Authors: Levesque MA, Katsaros D, Massobrio M, Genta F, Yu H, Richiardi G, Fracchioli S, Durando A, Arisio R, Diamandis EP
- Issue date: 2000 Aug